Zetiq Team Publishes Article in Journal of Histotechnology

Zetiq’s unique staining technology is the subject of an upcoming article in a peer-reviewed medical journal. The article, entitled Novel Histochemical Stain for Tinctorial Detection of Cancer and Neoplastic Cells, has been published in the Journal of Histotechnology. The article appears in Volume 32 (3), pages 97-106, 2009.

The article was authored by Pavel Idelevich, Don Kristt, Elimelech Okon, Dov Terkieltaub, Ilia Rivkin, Ami Fishman, Sylvia Lew, Eduardo Schejter, and Adi Elkeles.

About Zetiq:
Zetiq Technologies Ltd. develops effective cancer diagnostic tools. A significant medical need exists for early stage diagnostic tools for screening, monitoring or diagnosing cancer. Zetiq offers unique advantages in this market with its proprietary CellDetect® technology for differential staining and morphological visualization to differentiate between non cancer cells and a wide variety of cancer indications. The Company\'s products alleviate the process of locating and identifying suspected cancer cells, reduce error, simplify the process and have a potential to be fully automated.
Zetiq is a subsidiary of Bio-Light Life Science Investments, a management and holding company specializing in biomedical technologies. Bio-Light is traded on the Tel Aviv Stock Exchange under the symbol TASE: BOLT.

For further information please contact:
Dr. Adi Elkeles
CEO
Zetiq Technologies Ltd.

www.zetiq.co.il
adi@bio-light.co.il